Cullinan Therapeutics/$CGEM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cullinan Therapeutics
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
- Ticker
- $CGEM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 109
- Headquarters
- Cambridge, United States
- Website
- cullinantherapeutics.com
CGEM Metrics
BasicAdvanced
$967M
-
-$3.47
0.02
-
Price and volume
Market cap
$967M
Beta
0.02
52-week high
$23.19
52-week low
$6.73
Average daily volume
973K
Financial strength
Current ratio
8.417
Quick ratio
8.293
Long term debt to equity
0.004
Total debt to equity
0.006
Profitability
EBITDA (TTM)
-221.489
Management effectiveness
Return on assets (TTM)
-31.36%
Return on equity (TTM)
-50.30%
Valuation
Price to book
3.01
Price to tangible book (TTM)
3.01
Price to free cash flow (TTM)
-5.667
Free cash flow yield (TTM)
-17.65%
Free cash flow per share (TTM)
-2.652
Growth
Earnings per share change (TTM)
4.47%
3-year earnings per share growth (CAGR)
1.65%
What the Analysts think about CGEM
Analyst ratings (Buy, Hold, Sell) for Cullinan Therapeutics stock.
Analyst projections of the future price of Cullinan Therapeutics stock.
Bulls say / Bears say
Zipalertinib plus chemotherapy met its Phase 3 primary progression-free-survival endpoint in first-line EGFR exon 20 insertion lung cancer, and the FDA review process has begun. This gives Cullinan a potential route to commercial value beyond its earlier-stage programmes. (FT.com)
The autoimmune results are still early and based on small Phase 1 groups. CLN-978 also caused one Grade 3 cytokine-release syndrome event at the highest reported dose, and that dose cohort was stopped. (FT.com)
For post-platinum zipalertinib monotherapy, Phase 2b results showed a 35% confirmed response rate and a median response duration of 8.8 months. The FDA application remains under review, so approval and commercial uptake are not assured. (BusinessWire)
Cullinan remains loss-making, with a $53.7 million net loss in the second quarter and $356 million in cash and investments at June-end. The company expects that cash to last into 2029, but continued trial spending or delays could increase future financing needs. (FT.com)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
CGEM Financial Performance
Revenues and expenses
CGEM Earnings Performance
Company profitability
Upcoming events
No upcoming events
CGEM News
AllArticlesVideos
3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead
MarketBeat3 days ago
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
MarketBeat1 month ago
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Business Wire2 months ago
Funds containing CGEM
Fund name | Fund size | $CGEM weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.06% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.06% |
Xtrackers S&P 500 Swap£XSPX | $9.7B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.